Roche(RHHBY)
STAVANGER NORWAY, Norway
Pharmaceutical1 H-1B visas (FY2023)Focus: Small Molecules & Diagnostics
Roche is a life sciences company focused on Small Molecules & Diagnostics.
OncologyNeuroscienceImmunologyOphthalmologyInfectious Disease
Funding Stage
PUBLIC
Employees
100,000
Open Jobs
1087
Products & Portfolio (19)
31 discontinued products not shown
ACTEMRA
tocilizumab
Peak
mAbINTRAVENOUS, SUBCUTANEOUS · INJECTABLE
Interleukin 6 Receptor Antagonists
more Disease-Modifying Anti-Rheumatic Drugs (DMARDs)giant cell arteritis (GCA) in adult patientsactive polyarticular juvenile idiopathic arthritis in patients 2 years of age+10 more
2013
30
ACTEMRA
tocilizumab
LOE Approaching
mAbINJECTION · INJECTABLE
Interleukin 6 Receptor Antagonists
more Disease-Modifying Anti-Rheumatic Drugs (DMARDs)giant cell arteritis (GCA) in adult patientsactive polyarticular juvenile idiopathic arthritis in patients 2 years of age+10 more
2010
30
ACTIVASE
alteplase
LOE Approaching
SINGLE-USE · VIAL
CLINICAL PHARMACOLOGY Alteplase is an enzyme (serine protease) that has the property of fibrin-enhanced conversion of plasminogen to plasmin. It produces limited conversion of plasminogen in the absence of fibrin. Alteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin, thereby initiating local fibrinolysis (1). In patients with acute myocardial infarction administered 100 mg of Activase as an accelerated intravenous infusion over 90 minutes, plasma clearance occurred with an initial half‑life of less than 5 minutes and a terminal half‑life of 72 minutes. Clearance is mediated primarily by the liver (2). When Cathflo Activase is administered for restoration of function to central venous access devices according to the instructions in DOSAGE AND ADMINISTRATION, circulating plasma levels of Alteplase are not expected to reach pharmacologic concentrations. If a 2 mg dose of Alteplase were administered by bolus injection directly into the systemic circulation (rather than instilled into the catheter), the concentration of circulating Alteplase would be expected to return to endogenous circulating levels of 5–10 ng/mL within 30 minutes (1).
1987
30
ALECENSA
alectinib hydrochloride
Peak
ORAL · CAPSULE
RET. In nonclinical studies, alectinib inhibited ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, and decreased tumor cell viability in multiple cell lines harboring ALK fusions, amplifications, or activating mutations. The major active metabolite of alectinib, M4, showed similar in vitro potency and activity. Alectinib and M4 demonstrated in vitro and in vivo activity against multiple mutant forms of the ALK enzyme, including some mutations identified in NSCLC tumors in patients who have progressed on crizotinib. In mouse models implanted with tumors carrying ALK fusions, administration of alectinib resulted in antitumor activity and prolonged survival, including in mouse models implanted intracranially with ALK-driven tumor cell lines.
lung cancerlymphoma
2015
0
AVASTIN
bevacizumab
LOE Approaching
mAbINTRAVENOUS · VIAL
Vascular Endothelial Growth Factor-directed Antibody Interactions
recurrent glioblastoma (GBM) in adultsmetastatic renal cell carcinoma (mRCC)recurrent+10 more
2004
30
CATHFLO ACTIVASE
alteplase
LOE Approaching
INTRAVENOUS · VIAL
CLINICAL PHARMACOLOGY Alteplase is an enzyme (serine protease) that has the property of fibrin-enhanced conversion of plasminogen to plasmin. It produces limited conversion of plasminogen in the absence of fibrin. Alteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin, thereby initiating local fibrinolysis (1). In patients with acute myocardial infarction administered 100 mg of Activase as an accelerated intravenous infusion over 90 minutes, plasma clearance occurred with an initial half‑life of less than 5 minutes and a terminal half‑life of 72 minutes. Clearance is mediated primarily by the liver (2). When Cathflo Activase is administered for restoration of function to central venous access devices according to the instructions in DOSAGE AND ADMINISTRATION, circulating plasma levels of Alteplase are not expected to reach pharmacologic concentrations. If a 2 mg dose of Alteplase were administered by bolus injection directly into the systemic circulation (rather than instilled into the catheter), the concentration of circulating Alteplase would be expected to return to endogenous circulating levels of 5–10 ng/mL within 30 minutes (1).
1987
30
CELLCEPT
mycophenolate mofetil hydrochloride
LOE Approaching
INJECTION · INJECTABLE
(MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes. In vitro studies suggest that MPA modulates transcriptional activities in human CD4 T-lymphocytes by suppressing the Akt/mTOR and STAT5 pathways that are relevant to metabolism and survival, leading to an anergic state of T-cells whereby the cells become less responsive to antigenic stimulation. Additionally, MPA enhanced the expression of negative co-stimulators such as CD70, PD-1, CTLA-4, and transcription factor FoxP3 as well as decreased the expression of positive co-stimulators CD27 and CD28. MPA decreases proliferative responses of T- and B-lymphocytes to both mitogenic and allo-antigenic stimulation, antibody responses, as well as the production of cytokines from lymphocytes and monocytes such as GM-CSF, IFN-ɣ, IL-17, and TNF-α. Additionally, MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection. Overall, the effect of MPA is cytostatic and reversible.
organ rejectioncombination with other immunosuppressantsorgan rejection in adult+3 more
1998
30
CELLCEPT
mycophenolate mofetil
LOE Approaching
ORAL · CAPSULE
(MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes. In vitro studies suggest that MPA modulates transcriptional activities in human CD4 T-lymphocytes by suppressing the Akt/mTOR and STAT5 pathways that are relevant to metabolism and survival, leading to an anergic state of T-cells whereby the cells become less responsive to antigenic stimulation. Additionally, MPA enhanced the expression of negative co-stimulators such as CD70, PD-1, CTLA-4, and transcription factor FoxP3 as well as decreased the expression of positive co-stimulators CD27 and CD28. MPA decreases proliferative responses of T- and B-lymphocytes to both mitogenic and allo-antigenic stimulation, antibody responses, as well as the production of cytokines from lymphocytes and monocytes such as GM-CSF, IFN-ɣ, IL-17, and TNF-α. Additionally, MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection. Overall, the effect of MPA is cytostatic and reversible.
organ rejectioncombination with other immunosuppressantsorgan rejection in adult+3 more
1995
30
CELLCEPT
mycophenolate mofetil
LOE Approaching
ORAL · FOR SUSPENSION
(MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes. In vitro studies suggest that MPA modulates transcriptional activities in human CD4 T-lymphocytes by suppressing the Akt/mTOR and STAT5 pathways that are relevant to metabolism and survival, leading to an anergic state of T-cells whereby the cells become less responsive to antigenic stimulation. Additionally, MPA enhanced the expression of negative co-stimulators such as CD70, PD-1, CTLA-4, and transcription factor FoxP3 as well as decreased the expression of positive co-stimulators CD27 and CD28. MPA decreases proliferative responses of T- and B-lymphocytes to both mitogenic and allo-antigenic stimulation, antibody responses, as well as the production of cytokines from lymphocytes and monocytes such as GM-CSF, IFN-ɣ, IL-17, and TNF-α. Additionally, MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection. Overall, the effect of MPA is cytostatic and reversible.
organ rejectioncombination with other immunosuppressantsorgan rejection in adult+3 more
1998
30
CELLCEPT
mycophenolate mofetil
LOE Approaching
ORAL · TABLET
(MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes. In vitro studies suggest that MPA modulates transcriptional activities in human CD4 T-lymphocytes by suppressing the Akt/mTOR and STAT5 pathways that are relevant to metabolism and survival, leading to an anergic state of T-cells whereby the cells become less responsive to antigenic stimulation. Additionally, MPA enhanced the expression of negative co-stimulators such as CD70, PD-1, CTLA-4, and transcription factor FoxP3 as well as decreased the expression of positive co-stimulators CD27 and CD28. MPA decreases proliferative responses of T- and B-lymphocytes to both mitogenic and allo-antigenic stimulation, antibody responses, as well as the production of cytokines from lymphocytes and monocytes such as GM-CSF, IFN-ɣ, IL-17, and TNF-α. Additionally, MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection. Overall, the effect of MPA is cytostatic and reversible.
organ rejectioncombination with other immunosuppressantsorgan rejection in adult+3 more
1997
30
COLUMVI
glofitamab
Growth
BsAbINJECTION · INJECTABLE
CD20-directed Antibody Interactions
refractory diffuse large B-cell lymphomanot otherwise specified (DLBCLNOS)+4 more
2023
30
COTELLIC
cobimetinib
Peak
ORAL · TABLET
mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase 1 (MEK1) and MEK2. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E and K mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. In mice implanted with tumor cell lines expressing BRAF V600E, cobimetinib inhibited tumor cell growth. Cobimetinib and vemurafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Compared to either drug alone, coadministration of cobimetinib and vemurafenib resulted in increased apoptosis in vitro and reduced tumor growth in mouse implantation models of tumor cell lines harboring BRAF V600E mutations. Cobimetinib also prevented vemurafenib-mediated growth enhancement of a wild-type BRAF tumor cell line in an in vivo mouse implantation model.
metastatic melanoma with a BRAF V600EV600K mutationcombination with vemurafenib+1 more
2015
0
Pipeline & Clinical Trials
An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bon
Breast CancerClinical Trials (1)
NCT02553850An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat)
N/ASD Biosensor
Covid19Clinical Trials (1)
NCT04896710COVID-19 Rapid Testing for Self-Administration Among an Asymptomatic Sample
N/AImpact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Meta
Metastatic Kidney CancerClinical Trials (1)
NCT01336231Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer
N/AAn Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non
Non-Squamous Non-Small Cell Lung CancerClinical Trials (1)
NCT01358942An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)
N/ABlood samples collection
Infertility, FemaleClinical Trials (1)
NCT04387994Determination of Circulating Placental Biomarkers Levels to Predict the Pregnancy Outcome of First Trimester After IVF.
N/AIN-HOspital Program to systematizE Chest Pain Protocol (IN-HOPE)
Chest PainClinical Trials (1)
NCT04756362IN-HOspital Program to systematizE Chest Pain Protocol (IN-HOPE)
N/ARXDX-105
Cancers With RET AlterationsClinical Trials (1)
NCT03052569Expanded Access to RXDX-105 for Cancers With RET Alterations
N/AA Non-interventional Functional Magnetic Resonance Imaging (fMRI) Study and Behavioral Assessment in
Healthy VolunteerClinical Trials (1)
NCT02560142A Non-interventional Functional Magnetic Resonance Imaging (fMRI) Study and Behavioral Assessment in Healthy Participants
N/ABlood Sample
Acute Coronary SyndromeClinical Trials (2)
NCT06734117A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome
N/ANCT02984436High-Sensitivity Cardiac Troponin T to OPtimize Chest Pain Risk Stratification
N/AQuality of Life Questionnaire
Cervix CancerClinical Trials (1)
NCT02671071Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study
N/AThe ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.
Purpura, Thrombocytopenic, IdiopathicClinical Trials (1)
NCT01101295The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.
N/APegylated Interferon Alfa-2a
Hepatitis C, ChronicClinical Trials (5)
NCT00641654Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin
Phase 4NCT02263079A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
Phase 3NCT00221286Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients
Phase 3+2 more
AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Can
Breast CancerClinical Trials (1)
NCT01777932AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
N/ACellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allog
End Stage Renal DiseaseClinical Trials (1)
NCT00227045CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients
N/Abiological samples
Multiple SclerosisClinical Trials (1)
NCT05787795Identifying and Characterizing Preclinical MS
N/AAn Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL
Colorectal CancerClinical Trials (1)
NCT01276405An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)
N/AA Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Patients Wi
Rheumatoid ArthritisClinical Trials (1)
NCT01640548A Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Patients With Rheumatoid Arthritis
N/ASpinal Cord Stimulator
Spinal Muscular Atrophy Type 3Clinical Trials (1)
NCT05430113Spinal Cord Stimulation in Spinal Muscular Atrophy
N/ANo intervention
Non-Small Cell Lung CancerClinical Trials (5)
NCT07177352Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Phase 3NCT03611075A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)
Phase 1NCT02399072A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
N/A+2 more
Tocilizumab
Rheumatoid ArthritisClinical Trials (5)
NCT02682823Tocilizumab Real-Life Human Factors (RLHFs) Validation Study
Phase 4NCT03301883A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
Phase 4NCT01331837A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
Phase 4+2 more
Oseltamivir
InfluenzaClinical Trials (5)
NCT01249833Effect of Oseltamivir on Cognitive Function in Subjects With Influenza
Phase 4NCT01130636Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation
Phase 4NCT00412555A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.
Phase 4+2 more
Biomarker based adjustment of corticosteroid dose
Severe Persistent AsthmaClinical Trials (1)
NCT02717689A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma
N/ARituximab
Follicular LymphomaClinical Trials (1)
NCT02316613Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)
N/AUsual care
Multiple SclerosisClinical Trials (1)
NCT06634225Use of Inertial Units in Patient With Multiple Sclerosis (IMUSEP)
N/AGanciclovir
Cytomegalovirus InfectionsClinical Trials (5)
NCT00000768A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients
Phase 1NCT00000970A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir
Phase 1NCT00002024Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections
N/A+2 more
An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis
Rheumatoid ArthritisClinical Trials (1)
NCT01375478An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis
N/AAn Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in
Diffuse Large B-Cell LymphomaClinical Trials (1)
NCT01340443An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
N/ACounseling
Physical ActivityClinical Trials (1)
NCT01384838Exercise Training in Postmenopausal Patients With Breast Cancer
N/Aibandronate [Bonviva/Boniva]
Postmenopausal OsteoporosisClinical Trials (5)
NCT00551174A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
Phase 4NCT00545090ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
Phase 4NCT00545480SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
Phase 4+2 more
Artificial Pancreas
Diabetes Mellitus, Type 1Clinical Trials (1)
NCT02844517International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol
N/ANursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens
Colorectal CancerClinical Trials (1)
NCT01801085Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens
N/AFollow up to the AVANT Study up to 8 and 10 Years (Median Follow up) in Patients With Colon Carcinom
Colon Cancer Treated With Bevacizumab After Colon SurgeryClinical Trials (1)
NCT02228668Follow up to the AVANT Study up to 8 and 10 Years (Median Follow up) in Patients With Colon Carcinoma
N/Asoluble fms-like tyrosine kinase to placental growth factor ratio
Fetal Growth RetardationClinical Trials (1)
NCT05284474Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler
N/APeginterferon alfa-2a
Hepatitis C, ChronicClinical Trials (5)
NCT00948220Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C
Phase 4NCT00154869Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C
Phase 3NCT02791256A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6
Phase 3+2 more
Study of Anemia in Chronic Kidney Disease (CKD) Among High-Risk Hypertensive and Diabetic Patients i
Anemia, Diabetes, Kidney Disease, Chronic, HypertensionClinical Trials (1)
NCT02444845Study of Anemia in Chronic Kidney Disease (CKD) Among High-Risk Hypertensive and Diabetic Patients in Pakistan
N/A89Zr-atezolizumab PET scans
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedClinical Trials (1)
NCT03850028Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
N/ANo intervention
OsteoporosisSports activity
HIV SeropositivityClinical Trials (1)
NCT03920969Sport and Self Esteem in Patients Living With HIV
N/AThe Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience
Rheumatoid ArthritisClinical Trials (1)
NCT03109470The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience
N/ASpirometry
Idiopathic Pulmonary FibrosisClinical Trials (1)
NCT03261037A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period
N/Aepoetin beta
Infant, Low Birth WeightClinical Trials (1)
NCT00593801Erythropoietin Treatment in Extremely Low Birth Weight Infants
N/APIVKA-II and GAAD score calculation
Liver CirrhosisClinical Trials (1)
NCT07298577Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer
N/AAn Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With
Rheumatoid ArthritisClinical Trials (1)
NCT01392001An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)
N/AGenomic testing
Cancer of Unknown OriginMetronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Nega
Breast CancerClinical Trials (1)
NCT02012634Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
N/ABiomechanical Precision Medicine Registry for Patients With and Without Heart Failure
Heart Failure With Normal Ejection FractionClinical Trials (1)
NCT03480633Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
N/A2 online nutrition and exercise education classes
Gestational Diabetes MellitusClinical Trials (1)
NCT01681147Barriers to Adherence to Recommended Follow-up in Women With a History of Gestational Diabetes
N/Atest for SMN1 exon 7 deletion
Spinal Muscular AtrophyAn Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-
Non-Squamous Non-Small Cell Lung CancerClinical Trials (1)
NCT01790217An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)
N/Aacenocoumarol
AnticoagulantClinical Trials (2)
NCT01851824A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Phase 1NCT03154489Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care
N/AOpen Jobs (1087)
Patient Journey Partner Ophthalmology
Tunisia
2d ago
Head of Clinical Scientists, Oncology Early Clinical Development
Basel
Clinical Operations2d ago
Local Quality & Study Specialist
Dhaka
3d ago
（高级）治疗领域专员 - 血液治疗领域
Shanghai
3d ago
Legal Director
Sao Paulo
Legal & IP3d ago
Algorithm Researcher
Shanghai
4d ago
Application & Integration Architect
Indianapolis
4d ago
$106K - $196K/yr
(高级)治疗领域专员
Bengbu
4d ago
Employee Experience Operations IT Specialist (Japanese Speaking)
Petaling Jaya
IT4d ago
New Account Manager (1 de 2)
Lima
Commercial4d ago
Senior Data Analyst
Mannheim
4d ago
Field Product Manager
Finland
4d ago
Head of Process Science - Microstructuring
Mannheim
4d ago
Diagnostics Value Consultant(Product Marketing) - Diabetes Care Portfolio
Taipei
Commercial4d ago
Praktikum im Bereich Quality Assurance Packaging Vials für Studierende - RiKO (ab Sommer 2026, mind. 9 Monate)
Kaiseraugst
Quality4d ago
Production Technician
Indianapolis
Manufacturing4d ago
Strategic Account Executive
Detroit
4d ago
$105K - $195K/yr
Strategic Account Executive
New York City
4d ago
$110K - $215K/yr
Biologie- / Chemielaborant (m/w/d, befristet) in der Qualitätskontrolle, Standort Penzberg
Penzberg
4d ago
Medical Ecosystem Partner
San Jose, Costa Rica
4d ago
Associate (m/w/d) im Bereich Pharma Technical Development Europe Analytics
Penzberg
4d ago
Master im Umfeld Polymer Chemistry (m/w/d)
Penzberg
4d ago
Student Internship in ERP Treasury Management (starting in April 2025)
Kaiseraugst
Finance4d ago
Technical Asset Care Manager im Bereich Sterile Filling Asset CoRE (temporär für 2 Jahre)
Kaiseraugst
4d ago
Senior Principal Product Manager
Basel
4d ago
Interview Prep Quick Facts
Founded: 1896
Portfolio: 125 approved products, 174 clinical trials
Top TAs: Oncology, Infectious Diseases, Immunology
H-1B (2023): 1 approval
Publications: 25 in PubMed
Open Roles: 1087 active jobs
Portfolio Health
Pre-Launch15 (12%)
Growth6 (5%)
Peak24 (19%)
LOE Approaching75 (60%)
Post-LOE5 (4%)
125 total products
Therapeutic Area Focus
Oncology
19 marketed1751 pipeline
Infectious Diseases
7 marketed362 pipeline
Immunology
3 marketed296 pipeline
Neurology
3 marketed189 pipeline
Respiratory
1 marketed124 pipeline
Ophthalmology
4 marketed119 pipeline
Metabolic Diseases
113 pipeline
Hematology
109 pipeline
Marketed
Pipeline
Hiring Trend
Actively Hiring
1087
Open Roles
+1088
Added
-1
Filled/Removed
Based on last 2 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub